Moderna’s COVID-19 vaccine phase 2/3 pediatric trial underway

by on

Moderna’s COVID-19 vaccine phase 2/3 pediatric trial underway
Damareus Barbour CA
Mar 17, 2021

Moderna today announced the administration of first COVID-19 vaccine doses to participants between the ages of 6 months and 12 years old as part of a phase 2/3 clinical trial. 

The trial will investigate the vaccine’s effectiveness and safety in 6,750 healthy pediatric participants. For this study, Moderna will investigate two dosing levels for those ages 2 to 12, and three dosing levels for those aged 6 months to 2 years old.

Headline

Moderna’s COVID-19 vaccine phase 2/3 pediatric trial underway
Damareus Barbour CA
Mar 17, 2021

Moderna today announced the administration of first COVID-19 vaccine doses to participants between the ages of 6 months and 12 years old as part of a phase 2/3 clinical trial. 

The trial will investigate the vaccine’s effectiveness and safety in 6,750 healthy pediatric participants. For this study, Moderna will investigate two dosing levels for those ages 2 to 12, and three dosing levels for those aged 6 months to 2 years old.

COVID-19: Vaccines and Therapeutics

Headline

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: